Open Access<p>DPP-4 Inhibitor Linagliptin Ameliorates Oxidized LDL-Induced THP-1 Macrophage Foam Cell Formation and Inflammation</p>
Author(s) -
Haoran Wang,
Yue Li,
Xiaoliang Zhang,
Zhonglin Xu,
Jianping Zhou,
Wei Shang
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s249846
Subject(s) - linagliptin , foam cell , abca1 , cd36 , scavenger receptor , thp1 cell line , chemistry , inflammation , pharmacology , abcg1 , macrophage , cholesterol , cell culture , biochemistry , transporter , endocrinology , biology , diabetes mellitus , lipoprotein , receptor , immunology , type 2 diabetes , in vitro , gene , genetics
Atherosclerosis is one of the major causes of cardiovascular diseases. Lipid uptake and accumulation in macrophages play a major role in atherosclerotic plaque formation from its initiation to advanced atheroma formation. The dipeptidyl peptidase-4 (DPP-4) inhibitor Linagliptin is commonly used to lower blood glucose in type 2 diabetes patients. Recent studies report that Linagliptin has cardiovascular protective and anti-inflammatory effects.